Michael Tintiuc, MD MBA

Michael Tintiuc, MD MBA has extensive experience in global business development and licensing within the pharmaceutical industry. Michael has held various leadership positions in companies such as CaroGen Corporation, Medical Metrics, Inc., Hoya, IGY Immune Technologies & Life Sciences Inc., Micron, Inc. (Bio-Medical), Lumavita AG (Pharmaceutical), TEIJIN PHARMA LIMITED, WEX Pharmaceuticals Inc., and Dragon Pharmaceuticals, Inc.

In their most recent role as the Global Vice President of Business Development at CaroGen Corporation, Dr. Tintiuc leads international business development and licensing efforts. Michael is responsible for all global business development functions of the company.

Prior to that, they served as the Global Head of Business Development at Medical Metrics, Inc., where they were responsible for driving business development initiatives on a global scale.

As the Senior Director of Global Business Development and Product Strategy at Hoya, Dr. Tintiuc had a wide range of responsibilities including overseeing global operations, managing licensing contracts, conducting M&A activities, establishing international offices and laboratories, and filing patents.

At IGY Immune Technologies & Life Sciences Inc., Dr. Tintiuc held the position of Vice President of Global Business Development. In this role, they were responsible for international licensing, business development, and strategic partnerships. Michael successfully signed a licensing contract with a major Japanese multinational pharmaceutical company during their tenure.

During their time at Micron, Inc. (Bio-Medical), Dr. Tintiuc served as the Senior Director of Foreign Affairs and Business Development. Michael played a crucial role in signing collaboration agreements across North America, Europe, Asia, and Oceania, allowing Micron to establish a global presence. Additionally, they successfully in-licensed multiple cell lines from US institutions and out-licensed them to pharmaceutical companies worldwide.

As the Director of Business Development at Lumavita AG (Pharmaceutical), Dr. Tintiuc actively engaged in global licensing, business development, and M&A activities in various regions, including North and Latin America, Europe, and Asia. Michael signed licensing agreements for over 120 countries and managed alliances with existing partners.

Earlier in their career, Dr. Tintiuc served as the Deputy Manager of Global Marketing at TEIJIN PHARMA LIMITED, where they conducted global business development and marketing activities in Western and Eastern Europe, the Commonwealth of Independent States, Latin America, and the Middle East.

At WEX Pharmaceuticals Inc., Dr. Tintiuc held the position of Head of Business Development. Michael played a key role in developing the company's international business presence by working with pharmaceutical companies worldwide. Michael arranged a global deal with a major pharma company and managed alliances with European licensing partners.

Dr. Tintiuc began their career at Dragon Pharmaceuticals, Inc. as a Senior Manager of International Marketing. In this role, they signed licensing agreements for Latin America, Eastern and Central Europe, and Southeast Asia, with a cumulative value exceeding US $500 million. Michael also served as the alliance manager for the Middle East and India.

Overall, Dr. Tintiuc's work experience highlights their expertise in global business development, licensing, strategic partnerships, alliance management, and M&A activities within the pharmaceutical industry.

Michael Tintiuc, MD MBA, earned a Bachelor of Science (BSc) degree in Natural Sciences (Honours) from the University of Alaska Anchorage. Michael then pursued further studies at the State Medical and Pharmaceutical University of "N. Testemitsanu," where they obtained a Doctor of Medicine (MD) degree in Medical Education with a focus on General and Preventative Medicine. Additionally, they completed a Master of Business Administration (MBA) degree in International Marketing (Honours) from City University of Seattle.